Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2.

Vaccine - 8 May 2006

Smith Michael J, Teel Louise D, Carvalho Humberto M, Melton-Celsa Angela R, O'Brien Alison D

Abstract excerpt

The hemolytic uremic syndrome is a life-threatening sequela that occurs after infection with Shiga toxin (Stx)-producing Escherichia coli (STEC) or Shigella dysenteriae type 1, and Stx is responsible for initiating this syndrome. An STEC isolate can express Stx1, Stx2, or both, but antisera to Stx1 and Stx2 are not cross-neutralizing. To produce a single vaccine candidate against both toxins, we created a genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bacterial
Share to Escherichia coli Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Vitro Techniques

Share to Neutralization Tests

Share to Shiga Toxin 1

Share to Shiga Toxin 2

Share to Vaccines, Synthetic

Share to Vero Cells

Source

Identifiers

PMID: 16551486
DOI: 10.1016/j.vaccine.2006.02.035

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2.PMID 16551486Read ↗

Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing Anti-STa antibodies.Semantic proximity Read ↗

Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature.Semantic proximity Read ↗

Reduced Toxicity of Shiga Toxin (Stx) Type 2c in Mice Compared to Stx2d Is Associated with Instability of Stx2c Holotoxin.Semantic proximity Read ↗

Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin.Semantic proximity Read ↗

Isogenic Lysogens of Diverse Shiga Toxin 2-Encoding Bacteriophages Produce Markedly Different Amounts of Shiga ToxinSemantic proximity Read ↗

Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE ConferenceSemantic proximity Read ↗

Confronting Challenges to Enterotoxigenic Escherichia coli Vaccine DevelopmentSemantic proximity Read ↗

Structural and Functional Characterization of Stx2k, a New Subtype of Shiga Toxin 2Semantic proximity Read ↗

Treatment of STEC infection via CRISPR-Cas targeted cleavage of the Shiga toxin gene in animal modelsSemantic proximity Read ↗

Structure of Shiga Toxin Type 2 (Stx2) from Escherichia coli O157:H7Semantic proximity Read ↗

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I StudySemantic proximity Read ↗

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.